Related references
Note: Only part of the references are listed.Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Fei Tang et al.
CELL AND BIOSCIENCE (2018)
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches
Edwin R. Parra et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
Neus Martinez-Bosch et al.
CANCERS (2018)
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Treatment-naive HPV plus head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
Steven F. Gameiro et al.
ONCOIMMUNOLOGY (2018)
Immunotherapy against cancer-related viruses
Haruko Tashiro et al.
CELL RESEARCH (2017)
Update on immune checkpoint inhibitors in gynecological cancers
Valerie Heong et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Immune Cell Population in Ovarian Tumor Microenvironment
Dong Li Cai et al.
JOURNAL OF CANCER (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
Vasiliki Pelekanou et al.
BREAST CANCER RESEARCH (2017)
Biomarkers of response to PD-1/PD-L1 inhibition
Saman Maleki Vareki et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
Hye Ryun Kim et al.
SCIENTIFIC REPORTS (2016)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Immune infiltration and prostate cancer
Amy Strasner et al.
FRONTIERS IN ONCOLOGY (2015)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Share Paper
